Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: Comparison of plasma protein adsorption patterns

Journal of Drug Targeting

Volumn 13, Issue 3, 2005, Pages 179-187

  Göppert, Torsten M ^a   Müller, Rainer H ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Brain targeting; Plasma protein adsorption; Polysorbate; Solid lipid nanoparticles; Two dimensional polyacrylamide gel electrophoresis

Indexed keywords

ALBUMIN; APOLIPOPROTEIN C2; APOLIPOPROTEIN E; DRUG CARRIER; IMMUNOGLOBULIN G; POLYSORBATE; POLYSORBATE 20; POLYSORBATE 40; POLYSORBATE 60; POLYSORBATE 80; SOLID LIPID NANOPARTICLE;

ADSORPTION; ARTICLE; BRAIN; COLLOID; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DELIVERY SYSTEM; DRUG TARGETING; HUMAN; HYDROPHILICITY; IN VITRO STUDY; IN VIVO STUDY; INTRAVENOUS ADMINISTRATION; LIPOPHILICITY; PRIORITY JOURNAL; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ADSORPTION; APOLIPOPROTEINS E; BLOOD PROTEINS; BRAIN; COLLOIDS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENBUCRILATE; HUMANS; INDICATORS AND REAGENTS; INJECTIONS, INTRAVENOUS; LIPIDS; MICROSPHERES; PARTICLE SIZE; POLYSORBATES; PROTEINS; SURFACE PROPERTIES;

EID: 18744413936     PISSN: 1061186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/10611860500071292     Document Type: Article

References (42)

1. Absolom DR. 1986. Opsonins and dysopsonins: An overview. Methods Enzymol 132:281-318.
2. Alyautdin R, Gothier D, Petrov V, Kharkevich D, Kreuter J. 1995. Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles. Eur J Pharm Biopharm 41:44-48.
3. Alyautdin RN, Tezikov EB, Ramge P, Kharkevich DA, Begley DJ, Kreuter J. 1998. Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: An in situ brain perfusion study. J Microencapsul 15:67-74.
4. Anderson NL, Anderson NG. 1991. A two-dimensional gel database of human plasma proteins. Electrophoresis 12:883-906.
5. Bellinzona M, Roser F, Matthies C, Samii M, Saini M. 2004. Biopolymer-mediated suramin chemotherapy in the treatment of experimental brain tumours. Acta Oncol 43:259-263.
6. Bjellqvist B, Pasquali C, Ravier F, Sanchez JC, Hochstrasser DF. 1993. A nonlinear wide-range immobilized pH gradient for two-dimensional electrophoresis and its definition in a relevant pH scale. Electrophoresis 14:1357-1365.
7. Blunk T, Hochstrasser DF, Sanchez J-C, Müller BW, Müller RH. 1993. Colloidal carriers for intravenous drug targeting: Plasma protein adsorption patterns on surface-modified latex particles evaluated by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis 14:1382-1387.
8. Chekhonin VP, Kabanov AV, Zhirkov YA, Morozov GV. 1991. Fatty acid acylated Fab-fragments of antibodies to neurospecific proteins as carriers for neuroleptic targeted delivery in brain. FEBS Lett 287:149-152.
9. Cook BC, Retzinger GS. 1992. Elution of fibrinogen and other plasma protein from unmodified and from lecithin-coated polystyrene-divinylbenzene beads. J Colloid Interface Sci 153:1-12.
10. Dehouck B, Fenart L, Dehouck MP, Pierce A, Torpier G, Cecchelli R. 1997. A new function for the LDL receptor: Transcytosis of LDL across the blood-brain barrier. J Cell Biol 138:877-889.
11. Douglas SJ, Davis SS, Illum L. 1986. Biodistribution of poly(isobutyl-cyanoacrylate) nanoparticles in rabbits. Int J Pharm 34:145-152.
12. Ehrlich P. 1906. Collected studies on immunity. New York: John Wiley & Sons. p 586.
13. Friden PM. 1995. Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier. J Control Release 46:117-128.
14. Gessner A, Paulke BR, Müller RH. 2000. Analysis of plasma protein adsorption onto polystyrene particles by two-dimensional electrophoresis: Comparison of sample application and isoelectric focusing techniques. Electrophoresis 21:2438-2442.
15. Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J. 1999. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res 16:1564-1569.
16. Harnisch S, Müller RH. 1998. Plasma protein adsorption patterns on emulsions for parenteral administration: Establishment of a protocol for two-dimensional polyacrylamide electrophoresis. Electrophoresis 19:349-354.
17. Hochstrasser DF, Harrington MG, Hochstrasser AC, Miller MJ, Merril CR. 1988. Methods for increasing the resolution of two-dimensional protein electrophoresis. Anal Biochem 173:424-435.
18. Hoogland C, Sanchez JC, Tonella L, Binz PA, Bairoch A, Hochstrasser DF, Appel RD. 2000. The 1999 SWISS-2DPAGE database update. Nucleic Acids Res 28:286-288.
19. Horbett TA, Brash JL. 1987. Proteins at interfaces: Currrent issues and future prospects. In: Brash JL, Horbett TA, editors. Proteins at interfaces. Washington D.C., USA: Am. Chem. Soc. p 1-33.
20. Illum L, Davis SS, Müller RH, Mak E, West P. 1987. The organ distribution and circulation time of intravenously injected colloidal carriers sterically stabilized with a block copolymer-poloxamine 908. Life Sci 40:367-374.
21. Kreuter J, Petrov VE, Kharkevich DA, Alyautdin RN. 1997. Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood-brain barrier using surfactant-coated nanoparticles. J Control Release 49:81-87.
22. Lenaerts V, Couvreur P, Christiaens-Leyh D. Joiris E, Roland M, Rollman B, Speiser P. 1984. Degradation of poly (isobutyl cyanoacrylate) nanoparticles. Biomaterials 5:65-68.
23. Lück, M. 1997 Plasma protein adsorption as potential key factor for controlled drug delivery with particulate carriers. PhD Thesis, Department of Pharmacy. Freie Universität Berlin, Berlin.
24. Lück M, Paulke BR, Schröder W, Blunk T, Müller RH. 1998. Analysis of plasma protein adsorption on polymeric nanoparticles with different surface characteristics. J Biomed Mater Res 39:478-485.
25. Maassen S, Fattal E, Müller RH, Couvreur P. 1993. Cell cultures for the assessment of toxicitiy and uptake of polymeric particulate drug carriers. STP Pharma Sci 3:11-22.
26. Moghimi SM, Muir IS, Illum L, Davis SS, Kolb-Bachofen V. 1993. Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum. Biochim Biophys Acta 1179:157-165.
27. Müller RH. 1991. Colloidal carriers for controlled drug delivery and targeting - modification characterization and in vivo distribution. Wissenschaftliche Verlagsgesellschaft Stuttgart, CRC Press: Boca Raton. p 379.
28. Müller RH, Heinemann S. 1989. Surface modelling of micro-particles as parenteral systems with high tissue affinity. In: Gurny R, Junginger HE, editors. Bioadhesion - possibilities and future trends. Germany: Wissenschaftliche Verlagsgesellschaft, Stuttgart. p 202-214.
29. Müller RH, Lucks JS. 1996. Arzneistoffträger aus festen Lipidteilchen, Feste Lipidnanosphären (SLN). European Patent EP 0605497.
30. Müller RH, Schmidt S. 2002. Path finder technology for the delivery of drugs to the brain. New Drugs 2:38-42.
31. Müller RH, Mäder K, Gohla S. 2000. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 50:161-177.
32. Müller RH, Lück M, Kreuter J. 2001. Medicament excipient particles for tissue specific application of a medicament, PCT-application. PCT/EP98/064299 (P53601)
33. Pardridge WM. 1996. Physiologic-based strategies for protein drug delivery to the brain. J Control Release 39:281-286.
34. Patel HM. 1992. Serum opsonins and liposomes: Their interaction and opsonophagocytosis. Crit Rev Ther Drug Carrier Syst 9:39-90.
35. Poehling H-M, Neuhof V, 1981. Visualization of proteins with a silver "stain": A critical analysis. Electrophoresis 2:141-147.
36. Rapoport SI. 1988. Osmotic opening of the blood-brain barrier. Ann Neurol 24:677-684.
37. Scanu AM. 1987. Plasma apolipoproteins: Gene structure, function, and variants. In: Putman FW, editor. The plasma proteins. Structure, function, and genetic control. Vol. V. New York: Academic Press, Inc. p 141-190.
38. Senior JH. 1987. Fate and behavior of liposomes in vivo: A review of controlling factors. Crit Rev Ther Drug Carrier Syst 3:123-193.
39. Wang JX, Sun X, Zhang ZR. 2002. Enhanced brain targeting by synthesis of 3′,5′-dioctanoyl-5-fluoro-2′-deoxyuridine and incorporation into solid lipid nanoparticles. Eur J Pharm Biopharm 54:285-290.
40. Weisgraber KH, Mahley RW, Kowal RC, Herz J, Goldstein JL, Brown MS. 1990. Apolipoprotein C-I modulates the interaction of apolipoprotein E with beta-migrating very low density lipoproteins (beta-VLDL) and inhibits binding of beta-VLDL to low density lipoprotein receptor-related protein. J Biol Chem 265:22453-22459.
41. Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ. 1999. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release 59:299-307.
42. Zara GP, Cavalli R, Bargoni A, Fundaro A, Vighetto D, Gasco MR. 2002. Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: Pharmacokinetics and distribution of doxorubicin in brain and other tissues. J Drug Target 10:327-335.